Literature DB >> 7682415

6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts.

J P Bökkerink1, E H Stet, R A De Abreu, F J Damen, T W Hulscher, M A Bakker, J A van Baal.   

Abstract

The effects of prolonged exposure to 2 and 10 microM 6-mercaptopurine (6MP) in the human lymphoblastic T-cell line MOLT-4 were studied with respect to cell-kinetic parameters, phosphoribosyl pyrophosphate (PRPP) and purine ribonucleotide levels, formation of 6MP-nucleotides, especially methyl-thio-IMP (Me-tIMP), DNA and RNA synthesis ([32P] incorporation), and [8-14C]6MP incorporation into newly synthesized DNA and RNA. The results provided new insights into the complex mechanism of action of 6MP in human malignant lymphoblasts. Exposure to 2 microM 6MP resulted in a rapid inhibition of purine de novo synthesis (PDNS) by increased levels of Me-tIMP, resulting in increased PRPP levels and decreased purine ribonucleotides, affecting cell growth and clonal growth, and less cell death. DNA synthesis decreased, associated with an increasing delay of cells in S phase. Incorporation of thioguanine nucleotides into newly synthesized DNA resulted in an increasing arrest of cells in G2 + M phase. RNA synthesis, initially decreased, recovered partially, associated with a recovery of purine ribonucleotides. New formation of 6MP-nucleotides (tIMP) was only detected within the first 24 hr, and 6MP levels in the culture medium were already undetectable after 6 hr of exposure to 2 microM, indicating a high rate of incorporation and complete conversion of 6MP within this period. Incorporation of 6MP-nucleotides into DNA was 5 times as high as incorporation into RNA. Exposure to 10 microM 6MP resulted in early cytotoxicity at 24 hr, associated with a complete inhibition of PDNS by a large pool of Me-tIMP and lower levels of purine ribonucleotides as compared to 2 microM 6MP. A more severe delay of cells in S phase was associated with an inhibition of DNA synthesis to 14% of control within the first 24 hr, and an arrest in G2 + M phase. Further increasing levels of Me-tIMP caused an arrest of cells and late cytotoxicity in S phase at 48 hr, preventing further progression into G2 + M phase. Our data suggest that inhibition of PDNS due to Me-tIMP is a crucial event in the mechanism of 6MP cytotoxicity. It is responsible for decreased RNA synthesis and decreased availability of natural deoxyribonucleotides, causing a delay of DNA synthesis in S phase. This enhances incorporation of 6MP as thioguanine nucleotides into DNA in the S phase and subsequent late cytotoxicity in the G2 phase. However, with high concentrations of 6MP, the large pool of Me-tIMP causes severe reduction of natural deoxyribonucleotides in lymphoblasts with an active PDNS.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682415     DOI: 10.1016/0006-2952(93)90045-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  15 in total

1.  Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine.

Authors:  B A Kaskas; E Louis; U Hindorf; E Schaeffeler; J Deflandre; F Graepler; K Schmiegelow; M Gregor; U M Zanger; M Eichelbaum; M Schwab
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

2.  Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.

Authors:  E Israeli; E Goldin; S Fishman; F Konikoff; A Lavy; Y Chowers; E Melzer; A Lahat; M Mahamid; H Shirin; E Nussinson; O Segol; A Ben Ya'acov; Y Shabbat; Y Ilan
Journal:  Clin Exp Immunol       Date:  2015-08       Impact factor: 4.330

3.  Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment.

Authors:  Gianluigi Zaza; Meyling Cheok; Wenjian Yang; John C Panetta; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  Blood       Date:  2005-05-19       Impact factor: 22.113

Review 4.  Therapeutic drug monitoring of antimetabolic cytotoxic drugs.

Authors:  L Lennard
Journal:  Br J Clin Pharmacol       Date:  1999-02       Impact factor: 4.335

5.  6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.

Authors:  C Cuffari; Y Théorêt; S Latour; G Seidman
Journal:  Gut       Date:  1996-09       Impact factor: 23.059

6.  Decrease in S-adenosylmethionine synthesis by 6-mercaptopurine and methylmercaptopurine ribonucleoside in Molt F4 human malignant lymphoblasts.

Authors:  E H Stet; R A De Abreu; J P Bökkerink; H J Blom; L H Lambooy; T M Vogels-Mentink; A C de Graaf-Hess; B van Raay-Selten; F J Trijbels
Journal:  Biochem J       Date:  1994-11-15       Impact factor: 3.857

7.  Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.

Authors:  U Hindorf; M Lindqvist; C Peterson; P Söderkvist; M Ström; H Hjortswang; A Pousette; S Almer
Journal:  Gut       Date:  2006-03-16       Impact factor: 23.059

8.  The absorption of 6-mercaptopurine from 6-mercaptopurine riboside in rat small intestine: effect of phosphate.

Authors:  A M Pennington; J R Bronk
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations.

Authors:  Sofie Haglund; Jan Taipalensuu; Curt Peterson; Sven Almer
Journal:  Br J Clin Pharmacol       Date:  2007-07-27       Impact factor: 4.335

10.  Gene expression and thiopurine metabolite profiling in inflammatory bowel disease - novel clues to drug targets and disease mechanisms?

Authors:  Sofie Haglund; Sven Almer; Curt Peterson; Jan Söderman
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.